Startseite Kongressberichte & Archiv ASCO20 Virtual Scientific Meeting Oral Sessions Skin Cancers

Melanoma/Skin Cancers

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)  
 
10000 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.
 
Alexander M. Eggermont, Christian U. Blank, Mario Mandalà, et al.
 
The abstract concludes: 
Pembrolizumab, administered at 200 mg every 3 weeks for up to 1 year as adjuvant therapy, provided, at a 3-yr median follow-up, a sustained improvement in RFS, which was clinically meaningful, in resected high-risk stage III melanoma. This improvement was consistent across subgroups. In the overall population, the 3-yr cumulative incidence of distant metastasis being the first recurrence was 22.3% (pembrolizumab group) vs 37.3% (placebo group) (HR 0.55, 95% CI 0.44-0.69). Clinical trial information: NCT02362594
—————————————————————————————————————————————————————————————————————————————
 
10001 Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD.
 
Axel Hauschild, Reinhard Dummer, Mario Santinami, et al.
 
The abstract concludes: 
This 5-year analysis confirms the long-term benefit of adjuvant D+T in pts with resected stage III BRAFV600E/K–mutant melanoma. Clinical trial information: NCT01682083
—————————————————————————————————————————————————————————————————————————————
 
10002 First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
 
Christian U. Blank, Irene L.M. Reijers, Thomas Pennington, et al.
 
The abstract concludes: 
Neoadj I1N3 treatment induced a high pRR with tolerable toxicity. TLND was omitted in a major subset of pts, reducing surgical morbidity. Longer FU is needed to report safety and RFS when TLND is omitted in MPR pts. Clinical trial information: NCT02977052
—————————————————————————————————————————————————————————————————————————————
 
10003 A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.
SESSION
 
Michael A. Postow, Debra A Goldman, Alexander Noor Shoushtari, et al.
 
The abstract concludes: 
The first 2 doses of nivo + ipi appear to drive combo’s response efficacy and toxicity. Early radiographic imaging at week 6 may be able to identify pts who do not respond to combo dosing beyond dose 2. Randomized studies are planned to evaluate 1 dose of combo to see if efficacy is maintained with reduced toxicity. Clinical trial information: NCT03122522
—————————————————————————————————————————————————————————————————————————————
 
10004 Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.
 
Daniel Olson, Jason J. Luke, Andrew Stewart Poklepovic, et al.
 
The abstract concludes: 
This is the largest prospective study of IPI 1mg/kg + PEMBRO, demonstrating significant antitumor activity and tolerability in MEL post-PD1 Ab. Clinical trial information: NCT02743819
—————————————————————————————————————————————————————————————————————————————
 
10005 Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.
 
Ines Pires Da Silva, Tasnia Ahmed, Serigne Lo,et al.
 
The abstract concludes: 
In pts resistant to PD1, IPI+PD1 has higher RR, longer survival, yet similar high grade tox than IPI alone. Predictive models of response & survival will help select pts for IPI+/-PD1 after progressing on PD1.
—————————————————————————————————————————————————————————————————————————————
 
10006 Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.
 
Amod Sarnaik, Nikhil I. Khushalani, Jason Alan Chesney,et al.
 
The abstract concludes: 
Lifileucel treatment results in a 36.4% ORR and mDOR was not reached at 17.0 months of median study follow up in a heavily pretreated metastatic melanoma patients with high baseline disease burden who progressed on multiple prior therapies, including anti-PD1 and BRAF/MEK inhibitors, if BRAFv600 mutant. Clinical trial information: NCT02360579
—————————————————————————————————————————————————————————————————————————————
 
10008 Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).
 
Isabella Claudia Glitza, Suzanne Phillips, Courtney Brown, et al.
 
The abstract concludes: 
The trial demonstrates the feasibility of prospective clinical trials in MM patients with LMD. The combination of IT/ IV N was safe and well-tolerated, with no unexpected systemic or neurological toxicity. Final presentation will include results of LMD composite response assessment, comparative analysis of longitudinal CSF/blood samples to assess immunologic effects. Finally, the interim OS of the patients is encouraging, and supports further evaluation of IT administration of immunotherapy agents for pts with MM and LMD. Clinical trial information: NCT03025256
—————————————————————————————————————————————————————————————————————————————
 
Novel Immunotherapy Strategies
 
DISCUSSANT
Ryan J. Sullivan, MD | Massachusetts General Hospital
 
 
—————————————————————————————————————————————————————————————————————————————
 
Abstract from the clinical science symposium:

10009 Integrative tumor and immune cell multi-omic analyses to predict melanoma response to immune checkpoint blockade.

Valsamo Anagnostou, Daniel C. Bruhm, Noushin Niknafs,et al.

The abstract concludes: 
Our findings highlight the multi-faceted interactions between the tumor and the immune system and the importance of pre-existing T and B cell immunity in driving clinical response and PFS after immune checkpoint blockade, laying the groundwork for integration of genomic and immune features into predictive models that may ultimately optimize therapeutic decisions.
 
See the report in the ASCO DAILY NEWS: 
————————————————————————————————————————————————————————————————————————————
 
MORE ABSTRACTS:
 
Clinical Science Symposium
Systems Biology Approaches to Immunotherapy Response and Toxicity
 
Poster Discussion Session
Melanoma/Skin Cancers
 
Poster Session
Melanoma/Skin Cancers
 
ASCO Direct™ Focus – ASCO®20 Virtual Program  
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"  
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Melanoma/Skin (Abstracts #10000, 10001, 10002)
Access Content Now